Rheumatoid Arthritis: Statement Analysis
Statement b) is correct: joint involvement is usually symmetrical, and statement c) is correct: anti-CCP antibodies are highly specific for RA diagnosis. Statement e) is incorrect: patients with RA have significantly elevated cardiovascular risk compared to the general population.
Detailed Analysis of Each Statement
a) Distal Interphalangeal (DIP) Joint Involvement: FALSE
RA classically affects the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints, along with larger joints like wrists, shoulders, and knees. DIP joint involvement in RA is exceptionally rare, occurring in less than 0.2% of cases 1. When DIP joints are affected, this should prompt consideration of alternative diagnoses such as osteoarthritis or psoriatic arthritis rather than typical RA.
b) Symmetrical Joint Involvement: TRUE
Symmetrical polyarthritis is a hallmark clinical feature of rheumatoid arthritis. This symmetric pattern is one of the key distinguishing characteristics that differentiates RA from other forms of inflammatory arthritis. The distribution of affected joints—whether for swelling, bone erosions, or joint space narrowing—follows a symmetric pattern 2.
c) Anti-CCP Antibodies for Diagnosis: TRUE
Anti-citrullinated protein antibodies (anti-CCP) are highly specific for rheumatoid arthritis diagnosis 2, 3. Multiple studies demonstrate that anti-CCP antibodies have superior specificity compared to rheumatoid factor, with a positive predictive value approaching 100% in some cohorts 4. These antibodies:
- Precede the onset of disease symptoms, indicating pathogenetic involvement
- Serve as both diagnostic and prognostic markers
- Remain useful even in RF-negative presentations 5
- Are associated with more severe disease course and radiological destruction 2
Common pitfall: While anti-CCP is highly specific, it is not 100% sensitive—approximately 66.6% sensitivity in recent studies 4. Therefore, a negative anti-CCP does not exclude RA, particularly in early disease.
d) Biological Agents as First-Line Therapy: FALSE
Conventional synthetic DMARDs (particularly methotrexate) remain the first-line therapeutic choice for rheumatoid arthritis, not biological agents 6. The treatment algorithm follows this sequence:
- First-line: Conventional synthetic DMARDs (csDMARDs)
- Second-line: If inadequate response or intolerance to csDMARDs, then escalate to:
- TNF inhibitors
- Abatacept
- IL-6 inhibitors
- Rituximab
- JAK inhibitors (with specific cautions for patients ≥65 years with cardiovascular risk factors or smoking history)
Biological DMARDs are strongly recommended to be combined with conventional synthetic DMARDs (especially methotrexate) for optimal efficacy and survival rates 6.
e) Cardiovascular Risk: FALSE
Patients with RA have significantly elevated cardiovascular disease risk compared to the general population—the magnitude is comparable to that of diabetes mellitus 7. Key points:
- CVD risk in RA requires aggressive and targeted management
- Standard population-based CVD risk calculators underestimate risk in RA patients
- EULAR recommends applying a 1.5 multiplication factor to standard risk prediction models for RA patients
- Anti-CCP positivity itself correlates with higher incidence of ischemic heart disease, independent of classic cardiovascular risk factors 8
Critical clinical implication: Rheumatologists bear responsibility for cardiovascular risk management in RA patients, necessitating regular screening and aggressive modification of cardiovascular risk factors 7.
Summary of Correct Statements
- Correct: b) Symmetrical joint involvement, c) Anti-CCP specificity
- Incorrect: a) DIP involvement, d) Biologics as first-line, e) Equivalent CV risk